The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Observational cross-sectional study to evaluate the prognostic factors influencing the selection of bevacizumab combined with chemotherapy in patients with HER2-negative metastatic breast cancer in routine clinical practice. ONCOSUR-AVALOX study.
Luis Manso
No relevant relationships to disclose
Ramon Perez-Carrion
No relevant relationships to disclose
Jose Ignacio Chacon Lopez-Muniz
No relevant relationships to disclose
Andres Garcia Palomo
No relevant relationships to disclose
Elena Galve Calvo
No relevant relationships to disclose
Rosa M. Llorente
No relevant relationships to disclose
Javier Cassinello
No relevant relationships to disclose
Gustavo Catalan
No relevant relationships to disclose
Cristina Llorca
No relevant relationships to disclose
Maria Dolores Torregrosa
No relevant relationships to disclose
Inaki Alvarez
No relevant relationships to disclose
Isabel Gallegos Sancho
No relevant relationships to disclose
Esperanza Blanco
No relevant relationships to disclose
Mauro Oruezabal
No relevant relationships to disclose
Xabier Mielgo Rubio
No relevant relationships to disclose
Maria Jose Garcia Lopez
No relevant relationships to disclose
Blanca Hernando
No relevant relationships to disclose
Santos Enrech
No relevant relationships to disclose
Miguel Angel Lara
Honoraria - Roche
Hernan Cortes-Funes
No relevant relationships to disclose